Outsourcing

Meg Rivers is the former senior editor for 

Podcasts

In this episode of the Drug Solutions Podcast, Meg Rivers discusses outsourcing strategies in biopharma with Jeff Henderson, key account manager of Vetter.

Drug Solutions Podcast: Outsourcing vs. Insourcing in Biopharma: Determining the Best Strategy: Part 2

Chris Spivey is director of Industry Relations and Strategic Partnership, MJH Life Sciences.

In this episode of the Drug Solutions Podcast, Chris Spivey interviews executives at Shabas Solutions LLC, who ran the overseas QMM pilot project.

Drug Solutions Podcast: FDA Quality Management Maturity (QMM) Overseas Pilot Program Findings: Going Beyond the Regulations

Articles

CellVax Therapeutics has selected Theragent, a new CDMO, to manufacture clinical trial material for a new Phase II prostate cancer immunotherapy drug candidate.

CellVax and Theragent Form Manufacturing Pact for Novel Cancer Immunotherapy Drug Candidate

Under two new agreements, Societal CDMO will offer analytical, technical transfer, formulation, manufacturing, and packaging services for novel therapeutics.

Societal CDMO Signs Multiple CDMO Service Agreements

Brian Mullan is the chief technical officer of Yposkesi, an SK Pharmteco company.

Whether biologic manufacturers decide to outsource or develop products internally, the quality of a CDMO partnership is critical to success, especially for cell and gene therapy products.

Choosing the Right CDMO for CGT Programs 

In this episode of the Drug Solutions Podcast, John Koleng, VP of product development and manufacturing for TFF Pharmaceuticals shares outsourcing strategies in biopharma.

Drug Solutions Podcast: Outsourcing vs. Insourcing in Biopharma: Determining the Best Strategy: Part 1

Lonza and Israel Biotech Fund form a two-year agreement to support accelerated development and manufacture of biologics and small molecules.

Lonza, IBF Collaborate to Support Development and Manufacturing of Biologics and Small Molecules

Jennifer Markarian is a contributing editor for 

Pharmaceutical Technology spoke with Colleen Floreck, vice president, Global Marketing and Strategy, Catalent Cell and Gene Therapy about the specific requirements and challenges for expanding production of viral vectors. 

Expanding Viral Vector Manufacturing

The booming cell therapy market has created a need for capacity that outsourcing partners are ready to fill.

Scaling Up Capacity for Cell Therapies

William Bakewell, PhD, is research fellow, GMP Lab, at PPD Clinical Research Services, Thermo Fisher Scientific.

Optimizing the use of partners for clinical trials depends on selecting the right contractor.

Contract Manufacturing, Biopharmaceutical Production